Partnerships
Turning potential into progress
At JCR, we are firm believers that two heads are better than one. It’s why we actively seek opportunities to combine our unique technology and expertise with visionary thinking, using our partnership models to drive innovation forward and bring next-generation products to patients.
Our mindset
Proactive
We harness breakthrough therapeutic platforms like J-Brain Cargo® to unlock new possibilities and expand accessibility across markets with high unmet treatment needs.
Focused
We take a special interest in delivering precision therapies to target conditions that have traditionally been difficult to treat.
Innovative
We continuously find ways to push scientific boundaries and remain at the forefront of solving complex healthcare challenges.
Advancing care together
We leverage our cutting-edge facilities and portfolio to accelerate the research, development, and manufacturing of life-changing treatments.
Through continuous collaboration and dynamic partnership models, we can provide the tools and flexibility needed to streamline clinical development and deliver new treatments with precision and speed.
Ways to partner
Platform based
J-Brain Cargo®
Our proprietary technology J-Brain Cargo® is the world’s first approved platform that can help drugs cross the blood-brain barrier, enabling ground-breaking targeted delivery directly to the brain.
It has the potential to develop therapies that penetrate the central nervous system (CNS) and treat diseases throughout the body, unlocking new treatment possibilities for a wide range of conditions, including those in neurodegeneration, neuro-inflammation and neuro-oncology.
Gene therapy
Reimagining gene therapy
Since 2017, we have been pioneering the fusion of J-Brain Cargo® with adeno-associated virus (AAV) technology, as well as other applications that, together, could protect, prevent, and even cure diseases never thought possible before.
Already, J-Brain Cargo® has demonstrated the ability to deliver gene therapies precisely to the brain in pre-clinical trials, all while significantly reducing the associated risks and improving their efficacy.
See how J-Brain Cargo® is shaping the future of gene therapy today.
Asset based
Making treatment globally accessible
We are proud to offer an extensive portfolio of innovative treatments in clinical development, including our therapy for Mucopolysaccharidosis type II (MPS II) which is approved in Japan and already making a meaningful difference. Our pipeline also features promising therapies for other lysosomal storage disorders (LSDs) such as MPS I and MPS IIIA, along with additional pre-clinical assets.
These therapies present a unique opportunity to expand access to life-changing healthcare solutions globally, addressing both regulatory requirements and diverse patient needs. Through strategic licensing and co-clinical development partnerships, we aim to accelerate the global commercialization of these treatments so that they can reach patients worldwide.
“At JCR, our industry-leading J-Brain Cargo® technology facilitates the delivery of biologics across the blood-brain barrier into the central nervous system (CNS), targeting the neurological signs and symptoms of devastating, life-threatening diseases. We offer partnership opportunities to license our transformative lysosomal storage disorder (LSD) pipeline assets or to leverage our J-Brain Cargo® technology across research, manufacturing, and clinical development.”
Toshihiro Ishikiriyama
Senior Managing Executive Officer, Executive Director, Business Development Division
Partner testimonials
“Through this strategic collaboration with JCR, a company with a wealth of biotechnological expertise, we will combine our respective strengths to explore the use of biologics in this area and accelerate critically needed treatment options for people living with epilepsy.”
Jacopo Andreose
CEO of Angelini Pharma
“By leveraging JCR’s J-Brain Cargo® technology platform and manufacturing expertise, we strive to deliver innovative medicines to patients and families affected by rare lysosomal storage disorders. We aim to bring hope to patients and their families living with rare diseases.”
Shuichi Watanabe
Representative Director, President and CEO, MEDIPAL HOLDINGS CORPORATION
“The combination of our proprietary (CRISPR-GNDM®) epigenetic editing technology with J-Brain Cargo® could lead to a significant breakthrough that maximizes the value and potential for the treatment of CNS diseases.”
Haruhiko Morita
CEO of Modalis
Partner with us
Curious where we can go together?
Get in touch with our partnerships team at jcrbd@jp.jcrpharm.com.